GET DAILY SIGNALSZoetis (ZTS) Q3 2026 Earnings: Revenue Decline Offset by EPS Beat and Raised Guidance
Key Takeaways
- Zoetis reported third quarter 2026 revenue of $2.4 billion, down 1% year over year on both a reported and organic operational basis.
- Adjusted earnings per share (EPS) came in at $1.75, above the consensus estimate of roughly $1.51, while revenue of $2.39 billion also topped expectations near $2.33 billion.
- Weakness in companion animal care, especially the dermatology franchise, offset stronger performance in livestock and diagnostics.
- Management narrowed full-year 2026 revenue guidance to $9.22–$9.32 billion and raised adjusted EPS guidance to $6.25–$6.35.
- The U.S. segment declined 6%, while the International segment grew 4%, reflecting diverging demand trends across markets.
Earnings Context and Why It Matters
As the world's largest animal health company, Zoetis (ZTS) sits at the intersection of pet-care spending and agricultural demand. Its quarterly results offer a broad read on consumer health: companion animal products reflect how much households are willing to spend on pets, while livestock products track protein demand and producer economics. This report arrived during a period of softer U.S. veterinary clinic visits, rising care costs, and intensifying competition in key franchises such as dermatology and anti-infectives. Against that backdrop, I was watching closely to see whether Zoetis's diversified portfolio could cushion companion animal pressure and whether management would update its full-year outlook with confidence.
Reported Results
For the third quarter of 2026, Zoetis (ZTS) posted revenue of $2.4 billion, a 1% decline year over year. Adjusted diluted EPS was $1.75, up 3% on a reported basis, while GAAP diluted EPS was $1.44, down 12%. Both adjusted EPS and revenue beat consensus estimates of about $1.51 and $2.33 billion, respectively. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Segment performance was mixed. U.S. revenue of $1.2 billion fell 6%, pressured by an 8% decline in companion animal products tied to dermatology competition, generic entrants, and lower clinic visits. International revenue of $1.1 billion rose 4%, helped by livestock and parasiticide growth. Adjusted gross margin was 71%, down 30 basis points on a reported basis, while adjusted net income declined 7% on an organic operational basis.
The company narrowed full-year revenue guidance to $9.22–$9.32 billion and raised adjusted EPS guidance to $6.25–$6.35, up from a prior range of $6.15–$6.25.
Market Reaction and Investor Sentiment
Despite the top- and bottom-line beats, Zoetis (ZTS) shares came under pressure following the report as investors weighed continued weakness in companion animal demand and a cautious tone on the pet economy. Management noted that U.S. clinic visits remain down about 3% year to date, with high housing costs affecting pet adoption and owners becoming more value-conscious. The raised guidance was a positive signal, but the underlying competitive and macro headwinds—particularly in dermatology and against generic products—kept sentiment guarded heading into 2027.
Forward Outlook and Key Factors to Monitor
Zoetis (ZTS) enters its fourth quarter with a narrowed revenue outlook and a higher adjusted EPS target, but management signaled it is planning prudently for 2027 and is not assuming improvements in the macro environment or pet-owner spending trends.
Investors will want to watch whether competitive pressures in dermatology and anti-infectives continue to moderate, and how the Simparica parasiticide franchise performs across the U.S. and international markets. New product approvals, including the expected U.S. approval of long-acting Cytopoint and Simparica Duo, represent potential catalysts that could broaden the portfolio and support franchise resilience.
Cost discipline will also matter. Management has emphasized productivity programs and share repurchases, which have supported adjusted EPS even as revenue declines. Meanwhile, livestock demand and companion animal diagnostics, which delivered double-digit growth, could help offset softer pet-care categories. Any shift in clinic visit trends, pricing, or generic competition will be central to the next several quarters.
Using Tickeron Tools in My Research
In my analysis of names like Zoetis (ZTS), I often turn to Tickeron’s AI-powered tools to cross-check patterns and compare setups across the sector. The AI Screener lets me filter for technical signals, fundamentals, and performance metrics quickly, helping surface relevant ideas without manual effort. It has become a practical part of my routine for staying on top of evolving opportunities in animal health and beyond.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ZTS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ZTS turned positive on October 06, 2026. Looking at past instances where ZTS's MACD turned positive, the stock continued to rise in 26 of 47 cases over the following month. The odds of a continued upward trend are 55%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on ZTS as a result. In 48 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
ZTS moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ZTS crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +6.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in 142 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 97 of 187 cases where ZTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
ZTS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. ZTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.709) is normal, around the industry mean (7.659). P/E Ratio (14.551) is within average values for comparable stocks, (0.330). ZTS's Projected Growth (PEG Ratio) (6.647) is slightly higher than the industry average of (2.202). Dividend Yield (0.024) settles around the average of (0.062) among similar stocks. P/S Ratio (3.299) is also within normal values, averaging (181.047).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a pet medication company
Industry PharmaceuticalsGeneric
Advertisement